NEWS
Will Provenge take a big bite out of Taxotere? Provenge is an immunotherapy, meaning the vaccine stimulates the immune system to attack a specific target, in this case prostate cancer cells. It incorporates an antigen commonly found in prostate cancer cells as well as so-called antigen presenting cells obtained from the patient’s blood…more
Forest teams up with AstraZeneca for promotion of new anti-infective – Forest’s late-stage drug Ceftaroline is meant for the treatment of complicated skin and skin structure infections (cSSSI) as well as community-acquired bacterial pneumonia (CABP).The contract involves co-development and commercialization of the drug in all markets other than the U.S., Canada and Japan. With this deal, Forest will receive substantial funds from its partner through signing fee, royalties from sales and payments tied to certain specific sales milestones…more
Whistleblower case against J&J (re: Procrit promotion) to proceed – Duxbury claims he sold $13 million of Procrit between 1992 through 1998, and that approximately 80 percent of those sales were “false or fraudulent claims for Medicare reimbursement.” McClennan sold more than $65 million of Procrit, and about 50 percent of his sales were fraudulent Medicare claims, he alleges…more
The changing climate and practices at Henry Ford Hospital for drug reps. Would be surprised to see this as a template for others.
From the Let’s See What the Future Holds files – blood pressure drug with efficacy for MS??
RECOMMENDED
Are you looking for a vendor/partner to help with a Corporate/HR/Training Innovation initiative? Contact me (stevew at impactiviti dot com) and I’ll point you in the right direction!
PLUS
8 natural phenomena you probably didn’t know about. AND – from my StickyFigure blog – The Power of Inertia. Is “good enough” good enough?
———-
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
